aripiprazole), the first injection of aripiprazole ER injectable should be Discontinuation rates due to side effects were low for both Abilify Asimtufii.
Conversion from oral to Abilify Asimtufii: administer initial 960 mg injection (Abilify Asimtufii), or 21 days (Aristada). How to discontinue oral formulations.
Treatment with ABILIFY solution for injection should be discontinued as soon as clinically appropriate and the use of oral aripiprazole should be initiated.
Aripiprazole was first approved under the brand name Abilify as an oral tablet formulation in 2024, followed by Abilify oral solution in 2024 (now discontinued), Abilify Discmelt orally disintegrating tablets in 2024 (now discontinued), and Abilify intramuscular injection in 2024 (now discontinued).
Treatment with aripiprazole solution for injection should be discontinued for all formulations of aripiprazole, excluding Abilify MyCite. (tablet with
After the first ABILIFY MAINTENA injection, administer oral aripiprazole ABILIFY MAINTENA, 1.8% discontinued ABILIFY MAINTENA treatment due to weight increase
Treatment with ABILIFY solution for injection should be discontinued as soon as clinically appropriate and the use of oral aripiprazole should be initiated.
Otsuka has discontinued Abilify Discmelt oral disintegrating tablets. The company has also discontinued the oral solution and injection. Trigen introduced aripiprazole oral disintegrating tablets in 2024. Abilify oral tablets and generic aripiprazole oral tablets are not affected.
Cover of Aripiprazole Prolonged Release Suspension for Injection (Abilify Maintena) (300 mg and discontinued patients (other than patients discontinued
Comments